Table V.

OVA Ag-specific functional responses by splenic CD8 T cells from mice receiving Tc1 or Tc2 effector cell therapya

TherapyDays PosttherapyStimulator or Target CellCytokine Productionb% Specific Lysis ± SEMc (E:T Ratio 100)
IFN-γ (U/ml/106 cells)IL-4 (pg/ml/106 cells)IL-5 (U/ml/106 cells)
Tc17EG.7-OVA851.0260.00.022.4 ± 0.8
EL40.00.00.00.0
14EG.7-OVA938.08.00.015.0± 1.0
EL40.00.00.00.0
21EG.7-OVA0.00.00.00.0
EL40.00.00.00.0
Tc27EG.7-OVA575.0350.011,625.015.3± 0.6
EL40.00.00.00.0
14EG.7-OVA0.040.01,095.00.0
EL40.00.00.00.0
21EG.7-OVA0.010.00.00.0
EL40.00.00.00.0
None7EG.7-OVA0.00.00.00.0
EL40.00.00.00.0
14EG.7-OVA0.00.00.00.0
EL40.00.00.00.0
21EG.7-OVA0.00.00.00.0
EL40.00.00.00.0
  • a Mice were injected i.v. with 5 × 105 B16-OVA tumor cells. After 7 days, 2 × 106 Tc1 or Tc2 effector cells were adoptively transferred into mice bearing established 7-day pulmonary tumors.

  • b Spleens (n = 2/group) were harvested at weekly intervals and CD8-enriched T cell populations were cultured for 48 h with mitomycin C-treated EG.7-OVA or parental EL4 tumor cells. Supernatants were harvested and analyzed for cytokines by ELISA.

  • c Spleens (n = 2/group) were harvested at weekly intervals and tumor-specific cytolytic activity of CD8-enriched T cell populations were assessed in a standard 5-h chromium release assay.